23andMe Raises More Than $50 Million in New Financing

23andMe Raises More Than $50 Million in New Financing
Company Sets Growth Goal Of One Million Customers, Reduces Price to $99 from $299

December 11, 2012

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--23andMe, Inc., the leading personal genetics company, today announced it has raised more than $50 million in a Series D financing. Participants in the financing include Yuri Milner, a new investor, as well as existing investors Sergey Brin, 23andMe CEO Anne Wojcicki, New Enterprise Associates, Google Ventures and MPM Capital. This investment will help the company achieve its growth goal of one million customers.

The Power of One Million People

Expanding the company's ability to reach and serve one million individuals supports 23andMe's goal to revolutionize health and wellness. It also will accelerate 23andMe's ability to create a powerful platform that enables researchers around the globe to make meaningful discoveries significantly faster than is currently possible. With this expansion, 23andMe, which currently has more than 180,000 customers, will aim to:

  •     Enable groundbreaking research by creating an exponentially larger collective of actively engaged, genotyped individuals;
  •     Help accelerate development of new treatments;
  •     Improve understanding of wellness and disease prevention; and
  •     Broaden access for people seeking to manage their health and well-being through direct access and greater understanding of their own genetic data.

"This financing represents our next step toward empowering one million individuals to approach their wellness in a completely different, personalized way. This is the beginning of a new era of health that is focused on affordable preventative care and personalized medicine," said 23andMe CEO Anne Wojcicki.

"A community of one million actively engaged individuals will be transformational for research. A community of this magnitude will improve researchers' ability to quickly answer questions about genetic function and the role of environmental factors. In addition, it will enable researchers to understand medication efficacy and side effects, in both medications that exist today and medications are that are in development," Wojcicki added.

Broadening Access: Lowering Price to $99

The Series D investment, combined with rapidly decreasing costs associated with genetic testing technologies, enables 23andMe to reduce the price of its Personal Genome Service to $99, effective immediately. The company will continue to evaluate optimal pricing strategies.

The investment also enables 23andMe to expand the necessary infrastructure to support growth in its research and operational capabilities, including product development, genetic research, software development, recruitment and marketing.

About 23andMe:

23andMe, Inc. is the leading personal genetics company dedicated to helping individuals understand their own genetic information through DNA analysis technologies and web-based interactive tools. The company's Personal Genome Service® enables individuals to gain deeper insights into their ancestry and inherited traits. The vision for 23andMe is to personalize healthcare by making and supporting meaningful discoveries through genetic research. 23andMe, Inc., was founded in 2006, and the company is advised by a group of renowned experts in the fields of human genetics, bioinformatics and computer science. More information is available at www.23andme.com.

Contacts

23andMe, Inc.
Catherine Afarian, 408-656-8872
[email protected]
or
Donald Cutler, 415-876-8561
[email protected]

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.